Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adicet Bio Inc (ACET)

Adicet Bio Inc (ACET)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,433
  • Shares Outstanding, K 9,578
  • Annual Sales, $ 0 K
  • Annual Income, $ -117,120 K
  • EBIT $ -121 M
  • EBITDA $ -116 M
  • 60-Month Beta 1.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.33

Options Overview Details

View History
  • Implied Volatility 452.06% (-134.62%)
  • Historical Volatility 68.91%
  • IV Percentile 81%
  • IV Rank 42.46%
  • IV High 1,064.59% on 11/03/25
  • IV Low 0.01% on 09/04/25
  • Expected Move (DTE 1) 1.36 (19.26%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 3,114
  • Open Int (30-Day) 2,904
  • Expected Range 5.70 to 8.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -3.22
  • Number of Estimates 2
  • High Estimate -2.86
  • Low Estimate -3.59
  • Prior Year -5.12
  • Growth Rate Est. (year over year) +37.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.41 +10.20%
on 02/05/26
9.00 -21.56%
on 01/26/26
-1.22 (-14.73%)
since 01/16/26
3-Month
6.41 +10.20%
on 02/05/26
11.15 -36.68%
on 11/28/25
-2.56 (-26.61%)
since 11/18/25
52-Week
6.41 +10.20%
on 02/05/26
17.44 -59.51%
on 10/13/25
-8.46 (-54.51%)
since 02/18/25

Most Recent Stories

More News
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen...

ACET : 7.06 (+0.28%)
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

Successfully completed meeting with FDA to align on and enable outpatient dosing of systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients with prulacabtagene leucel (prula-cel, formerly...

ACET : 7.06 (+0.28%)
Adicet Bio Announces Reverse Stock Split

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board...

ACET : 7.06 (+0.28%)
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted...

ACET : 7.06 (+0.28%)
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Announced positive preliminary safety and efficacy data from Phase 1 clinical trial of ADI-001 in patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE); data highlighted rapid and sustained...

ACET : 7.06 (+0.28%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted...

ACET : 7.06 (+0.28%)
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen...

ACET : 7.06 (+0.28%)
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Preliminary clinical data from the Phase 1 trial expected in 2H/2026

ACET : 7.06 (+0.28%)
Adicet Bio (ACET) Receives a Hold from Citizens JMP

In a report released today, Reni Benjamin from Citizens JMP reiterated a Hold rating on Adicet Bio. The company’s shares closed yesterday at $0.85.Elevate Your Investing Strategy: Take advantage of TipRanks...

ACET : 7.06 (+0.28%)
Truist Financial Remains a Buy on Adicet Bio (ACET)

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Adicet Bio today. The company’s shares closed yesterday at $0.85.Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

ACET : 7.06 (+0.28%)

Business Summary

Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.

See More

Key Turning Points

3rd Resistance Point 7.64
2nd Resistance Point 7.42
1st Resistance Point 7.24
Last Price 7.06
1st Support Level 6.84
2nd Support Level 6.62
3rd Support Level 6.44

See More

52-Week High 17.44
Fibonacci 61.8% 13.22
Fibonacci 50% 11.92
Fibonacci 38.2% 10.62
Last Price 7.06
52-Week Low 6.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar